181 related articles for article (PubMed ID: 7690698)
1. Disposition of tacrolimus (FK 506) in rabbits. Role of red blood cell binding in hepatic clearance.
Piekoszewski W; Chow FS; Jusko WJ
Drug Metab Dispos; 1993; 21(4):690-8. PubMed ID: 7690698
[TBL] [Abstract][Full Text] [Related]
2. Effect of hematocrit and albumin concentration on hepatic clearance of tacrolimus (FK506) during rabbit liver perfusion.
Chow FS; Piekoszewski W; Jusko WJ
Drug Metab Dispos; 1997 May; 25(5):610-6. PubMed ID: 9152601
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics and disposition of the oxytocin receptor antagonist L-368,899 in rats and dogs.
Thompson KL; Vincent SH; Miller RR; Colletti AE; Alvaro RF; Wallace MA; Feeney WP; Chiu SH
Drug Metab Dispos; 1997 Oct; 25(10):1113-8. PubMed ID: 9321512
[TBL] [Abstract][Full Text] [Related]
4. The disposition of 14C-labeled tacrolimus after intravenous and oral administration in healthy human subjects.
Möller A; Iwasaki K; Kawamura A; Teramura Y; Shiraga T; Hata T; Schäfer A; Undre NA
Drug Metab Dispos; 1999 Jun; 27(6):633-6. PubMed ID: 10348790
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetic and pharmacodynamic effects of coadministration of methylprednisolone and tacrolimus in rabbits.
Piekoszewski W; Chow FS; Jusko WJ
J Pharmacol Exp Ther; 1994 Apr; 269(1):103-9. PubMed ID: 7513355
[TBL] [Abstract][Full Text] [Related]
6. Factors affecting the pharmacokinetics of tacrolimus (FK506) in hematopoietic cell transplant (HCT) patients.
Jacobson P; Ng J; Ratanatharathorn V; Uberti J; Brundage RC
Bone Marrow Transplant; 2001 Oct; 28(8):753-8. PubMed ID: 11781626
[TBL] [Abstract][Full Text] [Related]
7. Effect of hematocrit on pharmacokinetics of tacrolimus in adult living donor liver transplant recipients.
Minematsu T; Sugiyama E; Kusama M; Hori S; Yamada Y; Ohtani H; Sawada Y; Sato H; Takayama T; Sugawara Y; Makuuchi M; Iga T
Transplant Proc; 2004 Jun; 36(5):1506-11. PubMed ID: 15251372
[TBL] [Abstract][Full Text] [Related]
8. Increased clearance of tacrolimus in children: need for higher doses and earlier initiation prior to bone marrow transplantation.
Mehta P; Beltz S; Kedar A; Graham-Pole J; Wingard JR
Bone Marrow Transplant; 1999 Dec; 24(12):1323-7. PubMed ID: 10627642
[TBL] [Abstract][Full Text] [Related]
9. Population pharmacokinetics of tacrolimus in adult kidney transplant recipients.
Staatz CE; Willis C; Taylor PJ; Tett SE
Clin Pharmacol Ther; 2002 Dec; 72(6):660-9. PubMed ID: 12496747
[TBL] [Abstract][Full Text] [Related]
10. Nonlinear dorzolamide pharmacokinetics in rats: concentration-dependent erythrocyte distribution and drug-metabolite displacement interaction.
Wong BK; Bruhin PJ; Barrish A; Lin JH
Drug Metab Dispos; 1996 Jun; 24(6):659-63. PubMed ID: 8781782
[TBL] [Abstract][Full Text] [Related]
11. Higher intracerebral concentration of tacrolimus after intermittent than continuous administration to rats.
Sakamoto Y; Makuuchi M; Harihara Y; Imamura H; Sato H
Liver Transpl; 2001 Dec; 7(12):1071-6. PubMed ID: 11753909
[TBL] [Abstract][Full Text] [Related]
12. [Pharmacokinetics and metabolic disposition of exogenous phosphocreatine in rats].
Zou LL; Li QS; Han GZ; Lü L; Xi H; Li JH
Yao Xue Xue Bao; 2011 Jan; 46(1):75-80. PubMed ID: 21465812
[TBL] [Abstract][Full Text] [Related]
13. Tacrolimus clearance is age-dependent within the pediatric population.
Przepiorka D; Blamble D; Hilsenbeck S; Danielson M; Krance R; Chan KW
Bone Marrow Transplant; 2000 Sep; 26(6):601-5. PubMed ID: 11041564
[TBL] [Abstract][Full Text] [Related]
14. Time-dependent disposition of tacrolimus and its effect on endothelin-1 in liver allograft recipients.
Min DI; Chen HY; Lee MK; Ashton K; Martin MF
Pharmacotherapy; 1997; 17(3):457-63. PubMed ID: 9165550
[TBL] [Abstract][Full Text] [Related]
15. Disposition of salmeterol xinafoate in laboratory animals and humans.
Manchee GR; Barrow A; Kulkarni S; Palmer E; Oxford J; Colthup PV; Maconochie JG; Tarbit MH
Drug Metab Dispos; 1993; 21(6):1022-8. PubMed ID: 7905380
[TBL] [Abstract][Full Text] [Related]
16. Toxicokinetics of deltamethrin and its 4'-HO-metabolite in the rat.
Anadón A; Martinez-Larrañaga MR; Fernandez-Cruz ML; Diaz MJ; Fernandez MC; Martinez MA
Toxicol Appl Pharmacol; 1996 Nov; 141(1):8-16. PubMed ID: 8917670
[TBL] [Abstract][Full Text] [Related]
17. Disposition of abouthiouzine: a novel antihyperthyroid drug.
Alkharfy KM; Khan RM; Al-Hadiya BM; Abou-Auda HS; Abou-Shaaban RR
Biopharm Drug Dispos; 2007 Apr; 28(3):105-11. PubMed ID: 17230598
[TBL] [Abstract][Full Text] [Related]
18. Tacrolimus pharmacokinetics in BMT patients.
Boswell GW; Bekersky I; Fay J; Wingard J; Antin J; Weisdorf D; Maher R; Fitzsimmons W; Nash R
Bone Marrow Transplant; 1998 Jan; 21(1):23-8. PubMed ID: 9486490
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetic properties of TDP4815 after single intravenous and oral administrations to rat, rabbit, monkey, dog and in vitro drug metabolism.
Chen Y; Cheng D; Tio C; Kagan N; Eisennagel S; Dasgupta M; Tomczuk B; Bone R; Huebert N
Biopharm Drug Dispos; 2008 Apr; 29(3):127-38. PubMed ID: 18186144
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics of tacrolimus in liver transplant patients.
Jusko WJ; Piekoszewski W; Klintmalm GB; Shaefer MS; Hebert MF; Piergies AA; Lee CC; Schechter P; Mekki QA
Clin Pharmacol Ther; 1995 Mar; 57(3):281-90. PubMed ID: 7535213
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
